Abstract:AI-based variant effect predictors (VEPs), such as AlphaMissense, which is based on the protein structure prediction method AlphaFold, have gained significant attention for their potential to predict pathogenic effects of mutations. However, the utility of these methods for identifying pathogenic mutations in cancer remains unknown. We sought to quantify the prevalence of variants of unknown significance (VUSs) across the pan-cancer, multi-institution AACR GENIE cohort (N=160,965 samples) and test the utility of VEPs (SIFT, PolyPhen, MutationAssessor, REVEL, CADD, and AlphaMissense), using publicly available mutation annotations from each method, for 1) Annotating known pathogenic somatic cancer variants across the GENIE cohort, using known benign single nucleotide polymorphisms as negative controls 2) Identifying VUSs associated with overall survival (OS) in two cohorts of patients with non-small cell cancer (NSCLC), the MSK-IMPACT NCSLC (N=8,690) and non-MSK AACR GENIE Biopharma Collaborative NSCLC (N=977) cohorts, and 3) Identifying VUSs associated with known genomic patterns of mutual exclusivity in the MSK-IMPACT NSCLC cohort. In the GENIE cohort, 79% of mutations identified were VUSs according to an FDA-recognized molecular knowledge database, with a wide range of VUS frequencies across genes. Among VEPs trained without prior human-annotated knowledge, CADD and AlphaMissense had the highest AUROCs (0.940, 95%CI 0.937-0.943 and 0.917, 95%CI 0.913-0.922 respectively) for predicting known cancer drivers, demonstrating the power of protein structure modeling or functional genomic data for enhancing cancer drivers prediction. All VEPs identified known driver mutations in tumor suppressor genes more accurately than oncogenes, highlighting the challenge in identifying gain-of-function mutations. We tested whether VUSs reclassified as pathogenic by VEPs are associated with prognosis using inverse probability of treatment-weighted Cox's propensity hazard models controlling for tumor mutational burden, treatment history, and other factors. VUSs reclassified as pathogenic by AlphaMissense and other VEPs in KEAP1 and SMARCA4 correlated with worse OS, comparable to that of known oncogenic mutations in those genes. Patients with tumors containing VUSs annotated as benign had similar OS to patients without analogous driver mutations. Finally, VUSs reclassified as oncogenic by AlphaMissense in genes within the RTK/RAS and NRF2 pathways followed expected patterns of mutual exclusivity, further suggesting biological validity. Despite not being trained to predict somatic effects in cancer, AI-derived mutation annotations can broaden the subset of annotated pathogenic variants in cancer and contribute to a more complete understanding of cancer genetics. Real-world outcomes and alteration patterns are additional benchmarks to consider when assessing the utility of VEPs in cancer. Citation Format: Thinh N. Tran, Chris Fong, Karl Pichotta, Anisha Luthra, Ronglai Shen, Yuan Chen, Michele Waters, Susie Kim, Gregory Riely, Debyani Chakravarty, Nikolaus Schultz, Justin Jee. AI-derived predictions improve identification of real-world cancer driver mutations [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1252.

Real-world evaluation of deep learning algorithms to classify functional pathogenic germline variants

Phenotypic evaluation of deep learning models for classifying germline variant pathogenicity

Discordance between a deep learning model and clinical-grade variant pathogenicity classification in a rare disease cohort

Extracting and calibrating population evidence of variant pathogenicity using biobank data

Classification of genetic variants using machine learning

Abstract 4884: Evaluating the utility of in silico variant annotation tools for cancer driver detection

Leveraging cancer mutation data to predict the pathogenicity of germline missense variants

AI-derived comparative assessment of the performance of pathogenicity prediction tools on missense variants of breast cancer genes

Gene-specific machine learning for pathogenicity prediction of rare BRCA1 and BRCA2 missense variants

Abstract 1252: AI-derived predictions improve identification of real-world cancer driver mutations

Deep Learning Techniques for Subtype Classification and Prognosis in Breast Cancer Genomics: A Systematic Review and Meta-Analysis

DrABC: deep learning accurately predicts germline pathogenic mutation status in breast cancer patients based on phenotype data

Evaluating Generative AI's Ability to Identify Cancer Subtypes in Publicly Available Structured Genetic Datasets

Generalising better: Applying deep learning to integrate deleteriousness prediction scores for whole-exome SNV studies

Advancing Breast Cancer Subtype Prediction and Mutation Analysis: Integrating Deep Learning and Machine Learning Techniques in Genomic Research

Comparing Rule-Based and Deep Learning Models for Patient Phenotyping

Deep Learning for Cancer Type Classification and Driver Gene Identification

PrimateAI-3D outperforms AlphaMissense in real-world cohorts

Machine learning predictions improve identification of real-world cancer driver mutations

Deep structured learning for variant prioritization in Mendelian diseases